SEC Filings
Kodiak Sciences Raises $69 Million As It Heads Toward Retinal Drug Approval Applications
Management expects cash to support operations into 2027, with December results ahead for its treatment of inflammation-related retinal swelling.
Kodiak Sciences (KOD) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Management expects cash to support operations into 2027, with December results ahead for its treatment of inflammation-related retinal swelling.
SEC Filings
Both drugs hit their primary goals in a pivotal late-stage wet AMD trial, clearing the way for a multi-indication FDA application before year-end.